Just before presstime for this issue of Cardiovascular Device Update, Boston Scientific (Natick, Massachusetts) and Guidant (Indianapolis) reported that the FTC granted antitrust approval for their $27.2 billion merger and they expected to finalize the deal April 21.

At long last, $27.2 billion Boston Sci/Guidant deal clears final FTC hurdle

January 2, 2015

Post Date: January 2, 2015

Table of Contents

Financial Disclosure: None of the authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients

Subscription Publication

Books & Study Guides

Group & Site Licenses

State CME/CE Requirements